As of January 22, 2026, the biosimilar bevacizumab market is identifying as a transformative force in global oncology, with its 2026 valuation contributing to a sector expected to reach $2.23 billion by 2029. The 2026 landscape is defined by a steady CAGR of 7.9%, driven by the expiration of key patents for the reference biologic, Avastin, and a global mandate for cost-effective cancer care....

As of January 22, 2026, the natural killer cell therapeutics market is identifying as the most disruptive sub-sector of immunotherapy, with its 2026 valuation reaching approximately $571 million to $985 million depending on the inclusion of directed antibodies. The 2026 landscape is defined by a explosive CAGR of 7.2% to 40.2%, as researchers pivot toward NK cells due to their superior safety...

As of January 22, 2026, the PD-L1 inhibitors market is identifying as a powerhouse of modern oncology, with its 2026 valuation reaching approximately $57.5 billion within the broader $70.8 billion PD-1/PD-L1 checkpoint inhibitor landscape. The 2026 landscape is defined by a high-velocity CAGR of 13.88% to 19.85%, spurred by the aggressive expansion of drug labels into early-stage "adjuvant"...

According to a new report published by Introspective Market Research, titled, Scaffold Technology Market by Type, Application, and End User, The Global Scaffold Technology Market Size Was Valued at USD 2.0 Billion in 2023 and is Projected to Reach USD 6.6 Billion by 2032, Growing at a CAGR of 14.2%. Introduction / Market Overview The global Scaffold Technology Market is...